COMMUNIQUÉS West-GlobeNewswire

-
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
24/04/2025 -
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
24/04/2025 -
Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress
24/04/2025 -
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
24/04/2025 -
ORYZON Raises €30 Million in Capital Increase
24/04/2025 -
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
24/04/2025 -
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
24/04/2025 -
Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained
24/04/2025 -
RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call
24/04/2025 -
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
24/04/2025 -
Composition of the Nomination Committee of Orion Corporation
24/04/2025 -
New survey shows that over 90% of animal owners trust and appreciate veterinary teams but underestimate the demands of the profession
24/04/2025 -
iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial
24/04/2025 -
Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer
24/04/2025 -
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
24/04/2025 -
Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique
24/04/2025 -
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
24/04/2025 -
Les dernières données sur l’élafibranor démontrent un profil de tolérance favorable et une efficacité significative dans la CSP, une deuxième indication dans les maladies rares du foie
24/04/2025 -
Pharming Group to report first quarter 2025 financial results on May 8
24/04/2025
Pages